Navegar por autor "Lavilla Rubira, Esperanza"

A personalized medicine ex vivo test to predict clinical response to first line induction therapy with idarubicin and cytarabine in patients with acute myeloid leukemia

2013- Lavilla Rubira, Esperanza

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

2003- Penarrubia, M. J.; Odriozola, J.; González, C.; Massagué, I.; Miguel, A.; [et al.]

Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

2025-05- Serrano, Josefina; Martínez-Cuadrón, David; Gil, Cristina; Bernal, Teresa; Tormo, Mar; [et al.]

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

2023- Bernal, T.; Moreno, A.F.; de LaIglesia, A.; Benavente, C.; García-Noblejas, A.; [et al.]

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

2023- Sargas, C.; Ayala, R.; Larráyoz, M.J.; Chillón, M.C.; Rodriguez-Arboli, E.; [et al.]

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

2021-06- Martínez-Cuadrón, David; Serrano, Josefina; Gil, Cristina; Tormo, Mar; Martínez-Sánchez, Pilar; [et al.]

Ex vivo pharmacological evaluation of 16 drugs in 60+ acute myeloid leukemia patients using whole bone marrow samples analyzed by automated flow cytometry

2013- Lavilla Rubira, Esperanza

High correlation between clinical responses to 1st line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by exvitech

2014- Lavilla Rubira, Esperanza

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

2025-11- Alfonso Pierola, Ana; Martínez-Cuadrón, David; Rodríguez-Veiga, Rebeca; Gil, Cristina; Martínez-Sánchez, Pilar; [et al.]

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

2023- Sargas, C.; Ayala, R.; Larráyoz, M.J.; Chillón, M.C.; Carrillo-Cruz, E.; [et al.]

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

2023- Salmanton-García, J.; Marchesi, F.; Koehler, P.; Weinbergerová, B.; ?olovi?, N.; [et al.]

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

2024- Martínez-Cuadrón, D.; Megías-Vericat, J.E.; Gil, C.; Bernal, T.; Tormo, M.; [et al.]

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

2023- Marchesi, F.; Salmanton-García, J.; Buquicchio, C.; Itri, F.; Besson, C.; [et al.]

Personalizing therapies with ex vivo pharmacological responses may uncover the differences between IDA-DNR-MIT among european AML protocols

2013- Lavilla Rubira, Esperanza

Pharmacological profile of cytarabine and idarubicin in patient samples (ex vivo) with newly diagnosed acute myeloid leukemia identifies responders vs non responders

2013- Lavilla Rubira, Esperanza

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine

2014- Lavilla Rubira, Esperanza

Pharmacological profiles of AML treatments in patient samples to personalize treatment.

2014- Fernandez Fernandez, Angeles; Lavilla Rubira, Esperanza

Population pharmacological profiles of aml treatments in patient samples by automated flow cytometry; a bridge to individualized medicine

2013- Lavilla Rubira, Esperanza

Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML

1999- Steegmann, Juan Luís; Odriozola, Jesús; Rodriguez Salvanés, Francisco; Giraldo, Pilar; García Laraña, José; [et al.]

Repositorio digital RUNA

Navegar por autor "Lavilla Rubira, Esperanza"

A personalized medicine ex vivo test to predict clinical response to first line induction therapy with idarubicin and cytarabine in patients with acute myeloid leukemia ﻿

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses ﻿

Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience ﻿

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry ﻿

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry ﻿

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group ﻿

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? ﻿

Ex vivo pharmacological evaluation of 16 drugs in 60+ acute myeloid leukemia patients using whole bone marrow samples analyzed by automated flow cytometry ﻿

High correlation between clinical responses to 1st line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by exvitech ﻿

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry ﻿

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry ﻿

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry ﻿

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry ﻿

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry ﻿

Personalizing therapies with ex vivo pharmacological responses may uncover the differences between IDA-DNR-MIT among european AML protocols ﻿

Pharmacological profile of cytarabine and idarubicin in patient samples (ex vivo) with newly diagnosed acute myeloid leukemia identifies responders vs non responders ﻿

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine ﻿

Pharmacological profiles of AML treatments in patient samples to personalize treatment. ﻿

Population pharmacological profiles of aml treatments in patient samples by automated flow cytometry; a bridge to individualized medicine ﻿

A personalized medicine ex vivo test to predict clinical response to first line induction therapy with idarubicin and cytarabine in patients with acute myeloid leukemia

A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

Autologous or Allogeneic Hematopoietic Stem Cell Transplantation as Front-Line Treatment for Adult Secondary Acute Myeloid Leukemia Patients: The PETHEMA Registry Experience

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Ex vivo pharmacological evaluation of 16 drugs in 60+ acute myeloid leukemia patients using whole bone marrow samples analyzed by automated flow cytometry

High correlation between clinical responses to 1st line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by exvitech

Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry

Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry

Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Personalizing therapies with ex vivo pharmacological responses may uncover the differences between IDA-DNR-MIT among european AML protocols

Pharmacological profile of cytarabine and idarubicin in patient samples (ex vivo) with newly diagnosed acute myeloid leukemia identifies responders vs non responders

Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine

Pharmacological profiles of AML treatments in patient samples to personalize treatment.

Population pharmacological profiles of aml treatments in patient samples by automated flow cytometry; a bridge to individualized medicine